CLINICAL_TRIALS
trial_result
· 2025-10-16
Clinical Trial Update: Nivolumab Combined With BMS-986253 in HCC Patients [Phase 2]
Summary
A Phase 2 study evaluating nivolumab in combination with BMS-986253 for hepatocellular carcinoma has been terminated, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: NYU Langone Health | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2025-10-16